The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Performance in Q1 was characterized by steady core operations and financial discipline despite seasonal volume headwinds from weaker flu activity and winter weather.

The Talkspace acquisition is a strategic pivot to create the industry's first end-to-end behavioral health continuum, bridging the gap between outpatient virtual care and high-acuity inpatient services.

Management attributed acute care margin strength to solid expense management and higher pricing contributions driven by an increase in high-acuity service lines like cardiology and neurology.

The company is scaling AI governance across two domains: administrative efficiency in revenue cycle operations and clinical operations to enhance patient experience and hospital-level efficiency.

Behavioral health volume growth is being supported by heavy staffing investments made in 2025, which are now allowing the company to capture strong market demand more effectively.

Strategic positioning in Nevada showed signs of recovery with adjusted admissions increasing 1.5%, signaling a stabilization in a key market after previous volatility.

Full-year 2026 guidance is reiterated, assuming a ramp-up in earnings as new facilities in Florida and D.C. mature and behavioral wage pressures continue to moderate.

The Talkspace transaction is expected to be accretive within the first 12 months, with a projected single-digit EBITDA multiple by the third year post-closing through bidirectional revenue synergies.

Management anticipates a $75 million pretax headwind for the year related to the expiration of health insurance exchange subsidies, with impact expected to steepen in the second half.

Volume growth is projected to become more balanced with pricing as the year progresses, assuming a normalization of seasonal trends and the addition of 178 new beds in Q2.

Capital allocation will remain focused on a minimum of $800 million to $900 million in share repurchases while maintaining leverage slightly above 2x to support M&A.

Q1 results included $46 million of out-of-period Medicaid supplemental payments from Nevada and Ohio, which were previously contemplated in the annual guidance.

Weather and weak respiratory activity impacted acute care volumes by approximately 200 basis points and behavioral volumes by 40 to 50 basis points.

A $15 million impact was recorded for health insurance exchange (HIX) dynamics, including a conservative reserve for potential non-payment of premiums by exchange members.

California nurse staffing ratio requirements taking effect June 1 represent a known headwind, though management remains on track with previously established cost assumptions.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management acknowledged that core EBITDA growth was not yet at the 5% target in Q1 when excluding non-recurring items like the $46 million DPP benefit.

Confidence in reaching the full-year target is based on the back-half contribution of new bed towers and the maturation of the Cedar Hill facility.

Eight AI use cases are already scaled in revenue cycle operations, specifically improving denials management and revenue capture.

Future clinical AI initiatives with partner Hippocratic AI will focus on hospital efficiency rather than core clinical decision-making in the near term.

High confidence exists for the approval of a $50 million Florida program, which could potentially yield a higher benefit than currently estimated.

The California program remains uncertain due to a lack of consensus between the state and CMS, and no benefit is currently included in the outlook.

Wage growth moderated to 6-7% in Q1 from 8% in 2025, with further moderation expected as hiring needs stabilize.

Turnover is improving from a peak of 50% toward 40%, though it remains above pre-COVID levels.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.